- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04741542
Safety of SP-420 in the Treatment of Transfusional Iron Overload
Phase 1, Open-Label, Dose Escalation Study to Assess the Safety of SP-420 in the Treatment of Transfusional Iron Overload
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Mays Cancer Center, UT Health San Antonio
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18
- Diagnosis of MDS or MF with transfusional iron overload
- Patients with MDS, will include only those with MDS Revised international prognostic scoring system (IPSS-R) risk group of intermediate, high, or very high.
- Patients with MF, will include only those with Dynamic International Prognostic Scoring System-Plus (DIPSS=Plus) risk category of intermediate-1, intermediate-2, and high risk.
- Patients with sickle cell disease and transfusional iron overload
- Not appropriate for other iron chelation therapy, per physician
- Received 10 or more units of packed red blood cells in the preceding 24 months and remains red cell transfusion dependent
- ECOG ≤ 3
- ALT ≤ 3 times the upper limit of the normal range
- Estimate glomerular filtration rate calculated using Cockroft Gault of ≥ 60 mL/min/1.73m2
- Serum ferritin ≥1000 ng/ml
- Willing to comply with all study procedures and be available for the duration of the study
- Able to take oral medication and be willing to adhere to study medication for 28 days
Female patient must be post-menopausal (no menses for > 12 consecutive months) or surgically sterile (i.e., bilateral oophorectomy, hysterectomy, or tubal sterilization; must agree to completely abstain for heterosexual intercourse; or, if sexually active, must agree to use 1 of the following methods for birth control from the date she signs the consent form until 30 days after final dose of the study drug.
- Progesterone implant
- Intrauterine device
- Combination of 2 highly effective birth control methods (e.g., diaphragm/or cervical cap with spermicide plus a condom, hormonal contraception plus a barrier method, partner with vasectomy conducted >60 days before screening visit plus a hormone or barrier method
- Male patients must agree to use 1 of the following methods for birth control from the date he signs the consent form until 30 days after final dose of the study drug: be surgically sterile by vasectomy conducted > 60 days before screening visit plus use a barrier method, or, must agree to completely abstain from heterosexual intercourse, or must agree to use a combination of 2 highly effective birth control methods (e.g., diaphragm/or cervical cap with spermicide plus a condom, hormonal contraception plus a barrier method), or have a post-menopausal partner plus barrier method.
Exclusion Criteria:
- History of kidney disease including the renal Fanconi syndrome
- Proteinuria on urine dipstick greater than trace positive
- Pregnant, intending to become pregnant during the study, or breastfeeding
- Receiving another investigational drug within 30 days or 3 half-lives of the discontinued investigational agent, whichever is greater, of signing consent
- History of significant hepatic impairment, defined by Child-Pugh class C
- Active hepatitis B or C disease, evidenced by positive viral PCR
- Symptomatic heart failure
- Receiving active cytotoxic chemotherapy or radiation therapy for a second malignancy (hormonal therapy or topical therapy for squamous cell/basal cell cutaneous tumors are allowed). Treatment of the underlying hematologic malignancy with azacytidine, decitabine, venetoclax, lenalidomide, or ruxolitinib is permitted. Treatment with the supportive care agents luspatercept or erythropoietin agonists is permitted.
- Concurrent treatment with Exjade/Jadenu (deferasirox), Desferal (deferoxamine), or Ferriprox (deferiprone) are not permitted. Patients are allowed to stop these chelators and participate in this trial 14 days after discontinuation of the other chelator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
Study subjects will receive a 14mg/kg starting dose of SP-420 three times a week
|
This study aims to establish the safety of SP-420 administered orally three times per week (TIW).
Other Names:
|
Experimental: Group B
Study subjects will receive a 28mg/kg starting dose of SP-420 three times a week
|
This study aims to establish the safety of SP-420 administered orally three times per week (TIW).
Other Names:
|
Experimental: Group C
Study subjects will receive a 42mg/kg starting dose of SP-420 three times a week
|
This study aims to establish the safety of SP-420 administered orally three times per week (TIW).
Other Names:
|
Experimental: Group D
Study subjects will receive a 56mg/kg starting dose of SP-420 three times a week
|
This study aims to establish the safety of SP-420 administered orally three times per week (TIW).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events
Time Frame: 28 Days
|
Count of adverse events induced by SP-420
|
28 Days
|
Completion at original dose
Time Frame: 28 Days
|
Number of subjects that completed the study at the original starting dose of that group
|
28 Days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Supreet Kaur, MD, UT Health San Antonio
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTMS 20-0138
- HSC20210039H (Other Identifier: UT Health Science Center San Antonio)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Iron Overload
-
Novartis PharmaceuticalsCompletedTransfusional Iron OverloadItaly
-
ApoPharmaCompletedTransfusional Iron OverloadEgypt, Cyprus, Oman, Saudi Arabia, Turkey
-
Novartis PharmaceuticalsCompletedChronic Iron OverloadGermany
-
Novartis PharmaceuticalsNot yet recruiting
-
Novartis PharmaceuticalsCompletedCardiac Iron OverloadTaiwan, Egypt, Thailand, Turkey, United Kingdom, Italy, Canada, Greece
-
Assiut UniversityUnknownPlatelet Changes in Cases of Iron Overload
-
ApoPharmaCompletedIron Overload Due to Repeated Red Blood Cell TransfusionsUnited States, Canada, Greece, Italy
-
Assiut UniversityUnknownPlatelet Changes in Cases of Iron Overload
-
ShireTerminatedIron Overload Due to Repeated Red Blood Cell TransfusionsCanada, United States, Thailand, Italy, United Kingdom
-
ShireTerminatedPharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation TherapyIron Overload Due to Repeated Red Blood Cell TransfusionsUnited States, Canada, Lebanon, Italy, Egypt
Clinical Trials on SP-420
-
Pharmacosmos A/SICON plcRecruitingBeta Thalassemia Major AnemiaDenmark
-
Abfero Pharmaceuticals, IncWithdrawnIron Overload | Beta-ThalassemiaThailand, Lebanon, Turkey, Canada
-
Sideris PharmaceuticalsTerminatedIron Overload | Beta-ThalassemiaUnited States, Canada, Lebanon, Thailand, Turkey
-
AmgenTerminatedRelapsed and/or Refractory Multiple MyelomaUnited States, Japan, Belgium, Australia, Switzerland
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruitingChronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Autoimmune Hemolytic Anemia | Monoclonal B-Cell Lymphocytosis CLL-TypeItaly
-
Boehringer IngelheimCompletedMultiple MyelomaGermany, France
-
Fotona d.o.o.UnknownStress Urinary IncontinenceCanada
-
L&C BioPROMeDisRecruitingHerniation, DiscKorea, Republic of
-
Ruijin HospitalRecruiting
-
Johnson & Johnson Private LimitedCompletedLymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-CellIndia